动物实验,2型糖尿病 z-bo 2020-08-25 418

　　Objective: To study the effect of camel milk (CM) on the body weight, blood glucose, blood lipid, insulin, PPARγ and TNF-α gene expression in type 2 diabetic rats.

　　Method: A high-fat diet and a small dose (30mg/kg) of streptozotocin (STZ) were injected intraperitoneally to induce type 2 diabetes rat models, which were divided into four groups, namely the normal control group was divided into (control group) Groups and models. (Model) group, weekly measurement of camel milk low-dose (CM-L) group (3.5 mg/kg d), camel milk high-dose (CM-H) group (10 mg/kg d), body weight and blood glucose... After 4 weeks of glucose tolerance test, after 4 weeks of administration, he died after decapitation. Blood lipids (TC, TG, HDL-C, LDL-C), insulin levels, PPARγ in adipose tissue, and TNF- in liver tissue were measured. Detect the expression of αmRNA.

　　Results: Compared with the normal control group, the weight of the model group rats was significantly reduced (P\u003c0.01), fasting blood glucose, glucose tolerance were 0, 30, 60, 120 minutes, and serum TC, TG and LDL-C content Both were significantly increased (P \u003cu\→ u0.01c0.01), HDL-C content decreased, and insulin level increased. CM can reduce weight loss in diabetic rats and reduce hyperglycemia. The CM-H group achieved a significant hypoglycemic effect in the 4th week of administration, and significantly reduced blood sugar at 30 minutes of glucose tolerance (P\u003c0.05). CM tends to reduce the content of TC, TG, LDL-C in diabetic rats, increase the content of HDL-C and reduce insulin. The CM-H dose group can significantly reduce the content of TG and LDL-C (P\u003c0.05). In the model group, compared with the normal control group, PPARγmRNA was significantly down-regulated (P\u003c0.05), while TNF-αmRNA was significantly up-regulated (P\u003c0.01). CM increases PPARγmRNA in diabetic rats. Among them, the difference in the CM-H group was statistically significant (P\u003c0.05). ), CM can reduce its TNF-αmRNA expression.

　　Conclusion: CM can reduce weight loss in type 2 diabetic rats and improve symptoms such as hyperglycemia, impaired glucose tolerance and dyslipidemia.